Each year, with the guidance of our Scientific Advisory Board and other advisors, the DTRF awards grants to promising research projects in desmoid tumor science. These are often multi-year grants and in some cases are funded in partnership with Desmoid Tumour Foundation of Canada (DFC).
The DTRF is pleased to announce our research grants awarded in 2023:
- Manon Braat, N.G.J.A., MD, University Medical Center Utrecht (UMCU), Magnetic resonance image-guided high intensity focused ultrasound for patients with desmoid type fibromatosis: the MAGNIFIED trial. Year 2 of 2.
- Cristabelle DeSouza, PhD, Stanford University, Activation of c-JUN modulates the transcriptional activity of CD63 serving as a novel target for the treatment of Desmoid Type Fibromatosis. Year 2 of 2.
- Eldad Elnekave, MD, Shaare Zedek Medical Center, Doxorubicin Eluting Embolization for Desmoid Fibromatosis, clinical trial. Year 1 of 3. Jointly funded by the DTRF and Desmoid Tumour Foundation of Canada (DFC).
- Peter Hohenberger, MD, University of Heidelberg, Germany, An evidence-based 2nd consensus on the treatment for desmoid Tumors. Year 1 of 1.
- Joanna Przybyl, PhD, Research Institute – McGill University Health Centre, Canada, Targeting hexosamine biosynthesis pathway for the treatment of desmoid tumors. Year 2 of 2. Jointly funded by the DTRF and Desmoid Tumour Foundation of Canada (DFC)
- Sameer Rastogi, MD, All India Institute of Medical Sciences, To see the early effect of sorafenib on cognition, cardiovascular and reproductive functions in patients with aggressive fibromatosis. Year 1 of 3.
For more information, visit our Funded Grants page.
